Antiepileptic drug CSF Cerebrospinal fluid GABA Gamma-aminobutyric acid OMIM Online Mendelian Inheritance in Man SSADH Succinate semialdehyde dehydrogenase AIM Gamma-aminobutyric acid (GABA) is a major modulator in brain maturation and its role in many different neurodevelopmental disorders has been widely reported. Although the involvement of GABA in different disorders has been related to its regulatory function as an inhibitory neurotransmitter in the mature brain, co-transmitter, and signalling molecule, little is known about its role as a clinical biomarker in neuropaediatric disorders. The aim of this study is to report the cerebrospinal fluid (CSF) free-GABA concentrations in a large cohort of patients (n=85) with different neurological disorders.
Gamma-aminobutyric acid (GABA) is a molecule that is widely distributed in the brain. It has some important properties: (1) it is an inhibitory neurotransmitter in the mature brain, synthesized from the excitatory neurotransmitter glutamate; (2) it is an excitatory neurotransmitter in the developing brain, and an imbalance between excitatory and inhibitory function has been linked to different neurodevelopmental disorders such as autism, intellectual disability, epilepsy, Rett syndrome, or fragile-X syndrome, among others; 1-3 (3) it has an important role as a co-transmitter, being released from presynaptic vesicles together with other neurotransmitters such as glutamate, acetylcholine, dopamine or histamine; 4 (4) GABA has a role in the pathophysiology of inborn errors of branched-chain amino-acid metabolism; 5 (5) it performs signalling functions and acts as a second messenger regulating the mechanistic target of rapamycin (mTOR), and influences cellular development, homeostasis, and autophagy. 6 There are no previous data reporting GABA values in cerebrospinal fluid (CSF) in large cohorts of neuropaediatric patients. Although there are a few reports on small groups of patients, they emphasize only the influence of antiepileptic drugs (AEDs) and mainly focus on patients with epilepsy.
autoimmune meningitis or encephalitis. The samples were selected if the different microbiological and biochemical analyses did rule out the previous suspicions.
Study setting and inclusion criteria
We included patients with different neurological manifestations for whom CSF analysis was required for diagnostic purposes. Between May 2013 and July 2016, we recruited 85 neuropaediatric patients (32 females [37.6%] and 53 males [62.4%]) for the analysis of GABA concentrations in CSF, following previously reported procedures. 9 All patients' biochemical results were compared with our reference values as established in comparison groups. 7, 10, 11 Criteria for subgroup classification From the whole cohort of patients, three main nosological subgroups were selected. We hypothesized that free-GABA levels in CSF might be altered in patients under treatment with AEDs, in patients with extensive anatomical lesions in cerebral cortex and basal ganglia, and in patients with known monogenic disorders, including inborn errors of metabolism.
Biochemical methods
Plasma and CSF amino acids were analysed by ionexchange chromatography with ninhydrin detection (Biochrom 30; Pharmacia Biotech, Biochrom, Cambridge Science Park, UK). Analyses of CSF neurotransmitters (3-ortho-methyldopa, 5-hydroxytryptophan, 5-hydroxyindoleacetic, and homovanillic acids) and pyridoxal-5 0 -phosphate were performed by high-performance liquid chromatography with electrochemical (Coulochem II; ESA, Chelmsford, MA, USA) and fluorescent (Perkin Elmer, series 200, Norwalk, CT, USA) detection according to previously reported procedures. 10, 11 CSF free-GABA analysis was performed by capillary electrophoresis with laser-induced fluorescence detection according to a previously reported procedure. 7 Free-GABA was analysed instead of total GABA to avoid determination of the GABA fraction attached to proteins, and other forms of GABA that did not reflect the active fraction of the neurotransmitter (such as homocarnosines, etc.).
Genetic diagnosis
Depending on clinical phenotype, we used the following methods:
(1) multiplex ligation-dependent probe amplification for intellectual disability (targeted regions); (2) next-generation sequencing with customized panels for synaptopathies (Table SI, online supporting information; i.e. Rett syndrome, Rett-like syndromes, neurotransmitter disorders, and proteins involving neurotransmission), 12 epileptic encephalopathies, and mitochondrial disorders (nuclear genes); (3) karyotype; (4) molecular analysis for fragile-X syndrome; (5) comparative genomic hybridization array 60K; and (6) for suspected mitochondrial DNA disorders, whole mitochondrial DNA sequencing, detection of mitochondrial DNA rearrangements, and/or the mitochondrial DNA content measurement following standard procedures.
13,14

Statistical analysis
To explore the data distribution and the normality of numeric variables, histograms and Q-Q plots were analysed. Because the data did not follow a Gaussian distribution, different non-parametric tests were applied. Spearman's correlation test was used to determine the correlations between CSF GABA concentrations and patients' ages, and with diverse biochemical markers in CSF (5-hydroxyindoleacetic acid, homovanillic acid, pyridoxal-5 0 -phosphate, and 5-methyltetrahydrofolate). To compare proportions between groups, v 2 or Fisher's exact tests were used. The statistical tests performed were two-tailed.
An a priori power calculation was performed, considering a total cohort of approximately 84 patients. When comparing proportions of occurrence of a binary variable between two groups with that of the total sample, using a bilateral v 2 test with 5% significance level, to have a power of at least 80% to detect those differences we would need a difference between the proportions in each group of at least 30%.
To describe the prevalence of GABA abnormalities, we classified GABA values as low, normal, or high considering the age group according to our own CSF GABA reference intervals. 7 Extreme GABA values were also reported. Alterations in radiological data, type of AED, and whether patients were good or bad responders were codified as categorical variables.
All analyses used SPSS version 23.0 (IBM Corp., Armonk, NY, USA); p<0.05 was considered statistically significant.
Ethical issues
All caregivers were informed of analysis results and consulted about genetic analysis for diagnostic purposes. All gave their written consent for the clinical procedure for this investigation. The ethics committee of Sant Joan de D eu Hospital, Barcelona, Spain, approved the study.
RESULTS
The entire cohort of patients
We report a cohort of 85 neuropaediatric patients classified using their predominant neurological syndrome: movement disorder (n=5), epileptic encephalopathy/epilepsy (n=37), intellectual disability/complex encephalopathy with or without behavioural disturbances (n=16), primary neurotransmitter defects (n=7), inborn errors of metabolism (n=10), suspected inborn errors of metabolism (n=4), and What this paper adds
• Homeostasis of GABA seems more vulnerable than that of monoamines in the developing brain.
• The highest GABA levels are found in the primary GABA neurotransmitter disorder SSADH deficiency.
• GABA alterations are not specific for any clinical or neuroimaging presentation.
others (n=6) (Fig. 1) . The lumbar puncture was performed at a median age of 4 years 11 months (range: from first day of life to 21y).
GABA had a mean value of 65.9nmol/L (minimum 9.0n-mol/L, maximum 270nmol/L). The lowest values were 9n-mol/L, which corresponded to three different patients: one with a suspected secondary defect of neurotransmitters (normal range for age 38-92nmol/L), one with early epileptic encephalopathy, and one with neonatal hypoglycaemia (normal range for age in these patients 16-88nmol/ L). The highest values were 216nmol/L and 270nmol/L (normal for age in these patients 38-92nmol/L), which corresponded to patients with primary neurotransmitter defects: amino-acid decarboxylase defect and succinic semialdehyde dehydrogenase deficiency respectively. There were 19 patients with low GABA levels (22.4%), 47 patients within the normal range (55%), and 19 patients with high GABA levels (22.6%). Interestingly, among these 19 patients with high GABA levels, we identified seven with primary neurotransmitter defects: four of them had high levels of GABA in CSF ranging from 133 in the case of a patient with tyrosine hydroxylase deficiency, 169nmol/ L in a patient with primary defect in serine biosynthesis, to 216nmol/L and 270nmol/L. The frequency of GABAaltered values did not change according to age or phenotypic classification.
We also studied the percentage of patients with abnormalities in dopamine and serotonin status by using CSF values for homovanillic acid and 5-hydroxyindoleacetic acid. Values for homovanillic acid were abnormal in 20.2% of the patients (low in 8.3%, high in 11.9%) and values for 5-hydroxyindoleacetic acid were abnormal in 23.8% (low in 20.2%, high in 3.6%). These results in our cohort were similar to other reported studies.
9,15 Furthermore, we also studied whether there were statistical associations between homovanillic acid and 5-hydroxyindoleacetic acid abnormalities and clinical phenotypes, type of AED, and whether patients were good or bad responders. We found no statistically significant association between any of these.
Subgroups of patients Under treatment with AEDs
There were 36 patients (13 females, 23 males) classified in this phenotypic group (Table I) . From the 37 patients initially identified, one patient was excluded because at the time of performing the lumbar puncture he had not yet started anticonvulsive treatment. There were 13 patients (36.1%) with abnormal CSF GABA values: five with low GABA levels and eight with high GABA levels. Twentythree patients with epilepsy (63.9%) had normal CSF GABA values.
Patients were classified depending on (1) whether they were under GABAergic treatment at the time of the lumbar puncture, (2) GABA CSF levels, and (3) response to AEDs (Fig. 2) .
GABAergic drugs in our cohort were considered as those that directly affect GABA concentration in the synaptic cleft: (1) valproic acid, which decreases succinate semialdehyde dehydrogenase and GABA-transaminase activities and increases glutamate decarboxylase activity; and (2) vigabatrin, which reduces GABA-transaminase activity. There were 25 patients with GABAergic treatment (67.6%), 11 patients who received non-GABAergic AEDs (29.7%), and one patient who became epileptic after the lumbar puncture was completed.
Following the classification of the International League Against Epilepsy, 16 patients were either responsive or nonresponsive, considering drug-resistant epilepsy as a failure of adequate trials of two tolerated, appropriately chosen, and used AED schedules to achieve sustained freedom from seizures. There were 12 responsive patients (32.4%) and 24 with drug-resistant epilepsy (64.9%).
There was no significant difference (p=0.544) for clinical response, whether patients received GABAergic AEDs or not (Fig. 2a) . Nor was there any statistical difference in the clinical outcome and better control of their epilepsy Gamma-aminobutyric acid (GABA) normal ranges (L, low; H, high; N, normal): demonstrating dependence on the GABA levels in CSF (p=0.601; Fig. 2b ). Finally, considering only those patients with the lowest CSF GABA levels, they did not tend to have a diminished control of their epilepsy (Fig. 2c) .
With anatomical impairment in basal ganglia or cerebral cortex
There were 10 patients classified in this group, considering those with extensive anatomical lesions (such as severe cortical atrophy), or severe hypoxic-ischaemic or metabolic event. Patients with only suspected focal cortical dysplasia were not included in this subgroup. The characteristics of their brain magnetic resonance imaging (MRIs), and their diagnostic and pharmacological treatments during lumbar puncture, are summarized in Table II .
Within the whole group there were three patients with low CSF GABA, six with normal CSF GABA, and one with high CSF GABA. The sample of patients was small and no consistent conclusions can be stated; however, there was a tendency towards normal GABA levels in CSF even in extensive lesions. When considering whether the pharmacological treatment could have had an influence on CSF GABA levels, no statistically significant differences were found between groups (p=0.554).
With confirmed monogenic diagnostic
There were 21 patients with a confirmed monogenic disorder, 13 of whom had an inborn error of metabolism (including neurotransmitter defects). Sixteen out of the 21 had impaired levels in CSF.
A summary of diagnoses, clinical presentation, characteristics of brain MRIs, treatment during lumbar puncture, and reports of GABA levels in the CSF of these patients is given in Table III , classified according to their GABA levels: eight out of the 21 had high GABA levels, five had normal levels, and another eight had low levels of free-GABA in CSF.
There were seven patients with primary neurotransmitter defects involving (1) synthesis of tetrahydrobiopterin (i.e. 6-pyruvoyl-tetrahydropterin synthase, dihydropteridine reductase, and autosomal recessive guanosine triphosphate cyclohydrolase I); (2) monoamines (serotonin and/or dopamine; i.e. tyrosine hydroxylase and aromatic L-amino-acid decarboxylase deficiencies); (3) GABA catabolism (i.e. succinate semialdehyde dehydrogenase [SSADH] deficiency); and (4) serine deficiency. There were also three patients with different channelopathies: patient P15 carried a mutation in a potassium channel, patient P40 had a mutation in a sodium channel, and patient P75 in a calcium channel. There were two patients with Leigh syndrome carrying mutations in the mitochondrial DNA gene ATP6 (patient P70) and in thiamine transporter-2 (patient P85). There was also another patient with mutations in the ATP6 gene, with a neuropathy, ataxia, and retinitis pigmentosa-like phenotype (patient P81). There were two patients with disorders affecting the metabolism of branched-chain amino acids: patient P81 had a maple syrup urine disease, and patient P67 had a mutation in branched-chain keto-acid dehydrogenase kinase. There was also one patient with glucose transporter-1 deficiency (patient P68).
DISCUSSION
Whereas monoamines have been widely explored, 17 little is known about GABA as a clinical biomarker except in a few monogenic disorders affecting GABA synthesis or breakdown, 18 namely pyridoxine-dependent epilepsy, GABA-transaminase deficiency, SSADH deficiency, and homocarnosinosis.
Previous studies of CSF monoamine alterations in large cohorts of neuropaediatric patients showed secondary abnormalities for both serotonin and dopamine metabolites at a rate of about 20%. 9, 15 Epileptic disorders, leukodystrophies, and mitochondrial diseases are among the most common to exhibit these secondary defects. Our GABA study reports that 44% of our patients presented with abnormal levels of this neurotransmitter (half low and half high). This finding points towards a greater vulnerability in the CSF GABA status than in biogenic amines. However, we did not find any particular phenotype or group of diseases in which GABA was particularly affected except for some specific neurometabolic conditions. This could be explained by the following reasons. First, it is possible that CSF free-GABA concentrations (which are in the low nanomolar range) might not reflect the GABAergic status in specialized brain areas (GABA may reach molar range in such areas). Other techniques, such as proton magnetic resonance spectroscopy, should be applied to investigate in vivo brain GABA levels. 19 Second, GABA is a very versatile molecule and might act as a neurotransmitter, a trophic factor, or a modulatory molecule. Lastly, GABA is distributed in two main pools in the brain, described as the neurotransmitter pool and the metabolic pool. 20 GABA is present in the synaptic cleft (when it acts as a neurotransmitter) and can be collected in a CSF sample, but is also present within neurons and astrocytes (as a molecule that participates in intermediate metabolism). All this points to the conclusion that GABA homeostasis is mainly the result of a whole and complex brain modulation between inhibitory and excitatory status, which can hardly be reflected through sampling and examining CSF GABA levels.
To the best of our knowledge, this is the largest cohort of neuropaediatric patients for whom CSF GABA levels have been reported. The diagnostic yield of the reported cohort was 21 confirmed monogenic disorders (24.7%). There is a potential bias in the study as lumbar puncture was not systematically performed on all neuropaediatric patients. In fact, lumbar puncture was specifically performed in patients with complex/severe neurological disorders of unknown origin and especially to eliminate treatable conditions (i.e. metabolic disorders). Another limitation of our study is that the statistical power of all comparison tests performed was low. Therefore, statistical differences should be interpreted with caution. For this reason, further studies with a bigger cohort of patients are needed in this field.
Patients under treatment with AEDs
In this subgroup of patients, we could not demonstrate significant differences among groups, suggesting that free-GABA CSF analysis has a limited value as a biomarker for AED treatment monitoring.
Patients with anatomical impairment in basal ganglia or cerebral cortex
Although GABA is a widely distributed neurotransmitter in the whole brain, 4 there are some specific regions with high GABAergic innervation. GABAergic interneurons are very rich in every layer of the human neocortex. 21 GABAergic neurons can be found in great quantity in basal ganglia and structures directly related to the striatum such as the amigdala and hippocampus. 22, 23 In our cohort of patients with anatomical impairment of these rich GABAergic regions, CSF values were not impaired. It is worth mentioning that this subgroup of patients was heterogeneous, ranging from those with cortical dysplasia to wide anatomical lesions in the basal ganglia.
Patients with confirmed monogenic diagnostic
As previously reported 18 and expected, high levels of GABA in CSF were found in patient P82 with a confirmed SSADH deficiency, a primary neurotransmitter defect affecting GABA catabolism (SSADH, Online Mendelian Inheritance in Man [OMIM] number 271980). In our cohort this was one of the few disorders in which high levels of CSF GABA acted as a biomarker, with the highest GABA value detected in the whole cohort.
Maple syrup urine disease (OMIM 248600) is a metabolic autosomal recessive disorder affecting branched-chain amino-acid metabolism (leucine, isoleucine, and valine). It has been reported that high leucine levels in particular can result in impaired glutamate status in astrocytes. 24 Alterations in glutamate and GABA have also been reported in a mouse model of maple syrup urine disease. 25 GABA is formed from glutamate; when glutamate is depleted, GABA is also expected to be low.
Branched-chain keto-acid dehydrogenase kinase (OMIM 614923) deficiency is a disorder affecting branched-chain amino acids, in this case with especially low levels of leucine, isoleucine, and valine. 26, 27 Since it is the opposite defect to maple syrup urine disease, high levels of GABA in CSF should be observed, as in patient P67. Thiamine transporter-2 deficiency (OMIM 607483) is an autosomal recessive disorder affecting the intracellular transport of thiamine, thus affecting the tricarboxylic acid cycle by directly impairing thiamine-dependent enzymes 28 such as the alpha-ketoglutarate dehydrogenase complex and pyruvate dehydrogenase complex. As a result, there is a decrease in metabolic intermediates and GABA precursors.
As expected, in this case (patient P85) GABA levels in CSF were low.
Recent work on ion-gated channelopathies and abnormalities in biogenic amines is also relevant. 29 It hypothesizes that disturbances in ion fluxes might impair synaptic vesicle release and cause abnormalities in the secretion/ uptake of neurotransmitters; however, we cannot report consistent findings for GABA levels in CSF and the patients from the cohort with mutations in ion channels (patients P15, P40, and P75).
Some patients with primary neurotransmitter defects are treated with L-DOPA. Since there is a recognized mechanism of GABA and dopamine corelease, 4 increased GABA levels in CSF would be expected in those patients. Unfortunately, consistent evidence of this cannot be reported, since these patients have variable levels of GABA. It is, however, of interest to highlight that patient P68 (glucose transporter-1 deficiency, OMIM 138140) and patient P15 (serine deficiency, OMIM 601815) had high GABA levels in CSF, without any GABAergic AED. This phenomenon may have a pathophysiological explanation, but further results from CSF analysis in other patients would be necessary to support this explanation.
CONCLUSIONS
GABA alterations do not seem to be more prevalent in specific neurological/neuroradiological phenotypes. Moreover, we present a large cohort of patients with different diagnoses and underlying disorders which made the sample heterogeneous and the results difficult to interpret. Above this, the power calculations in our sample gave evidence that the cohort was not large enough to extract consistent conclusions with statistical significance. Another limitation of our study was that GABA levels in CSF were not addressed over time, since the lumbar puncture was not normally repeated unless the diagnosis was unclear after the first lumbar puncture, or the patient had an acute decompensation suspected to be directly related to the levels of the different neurotransmitters or CSF amino acids.
Inborn errors of metabolism could be a group of disorders where GABAergic synaptic homeostasis is especially vulnerable. The characterization of GABA dysfunction in different categories of inborn errors of metabolism could lead the way to complementary therapeutic strategies. In other neuropaediatric disorders, therapeutic strategies could be addressed if an alteration in GABA levels in CSF is confirmed over time and there is a consistent role of GABA abnormalities in the patients' phenotype, which could not be concluded in our cohort of patients.
Free-GABA quantification probably does not reflect the GABA content in the brain. Therefore, other techniques such as brain spectroscopy to quantify GABA and glutamate could prove better alternatives in the methods used to further our understanding of brain metabolism to improve therapeutic approaches.
